Please login to the form below

Not currently logged in
Email:
Password:

Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

MSD launches EU’s first biosimilar Herceptin in UK

MSD launches EU’s first biosimilar Herceptin in UK

has insisted it can ride out the storm with new products such as multiple sclerosis therapy Ocrevus (ocrelizumab) and cancer drugs Perjeta (pertuzumab), Tecentriq (atezolizumab) and Alecensa (alectinib).

Latest news

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

  • Biogen cuts $217m deal for Karyopharm neurology drug Biogen cuts $217m deal for Karyopharm neurology drug

    Biogen reported 2017 revenues of $12.3bn, up 15% on the prior year, thanks to gains for its multiple sclerosis drugs, particularly Tecfidera (dimethyl fumarate) and rising royalties from Ocrevus (ocrelizumab) -

  • Roche’s Ocrevus is first primary progressive MS drug in EU Roche’s Ocrevus is first primary progressive MS drug in EU

    Roche’s CD20-targeting antibody Ocrevus has become the first and only drug to be approved in the EU for the primary progressive for of multiple sclerosis (PPMS). ... In the ORATORIO study, Ocrevus was able to slow disability progression by around 24%

  • Smartphone monitoring shows its worth in Roche MS trial Smartphone monitoring shows its worth in Roche MS trial

    The latest results from the FLOODLIGHT clinical trial programme show that additional, real-world data using smartphone or smartwatch technology given to patients treated with Roche’s MS therapy Ocrevus (ocrelizumab),

  • Ocrevus off to a flying start as Roche raises 2017 forecasts Ocrevus off to a flying start as Roche raises 2017 forecasts

    new multiple sclerosis drug Ocrevus, which brought in 192m Swiss francs ($200m) in its first quarter on the market. ... Ocrevus (ocrelizumab) only reached the market at the end of March, and Roche's decision to set a competitively low price for the drug

More from news
Approximately 11 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics